Senior Correspondent, London
Ben's Feed
Oct 24, 2014

AstraZeneca cancer drug pipeline gets boost from European green light

LONDON (Reuters) – AstraZeneca’s cancer drug pipeline received a boost on Friday, as European regulators recommended approval of an experimental medicine against ovarian cancer.

The green light from the European Medicines Agency (EMA) for olaparib, or Lynparza, is welcome news since the product hit a road bump in June when a U.S. panel voted against its accelerated approval.

Oct 24, 2014
Oct 24, 2014
Oct 23, 2014
Oct 23, 2014

Fixing ‘Ebolanomics’ in pursuit of vaccines and drugs

LONDON (Reuters) – As researchers from Africa to China to America race to develop vaccines and treatments to fight Ebola, health experts are grappling with the economics of a disease that until this year had been off the drug industry’s radar.

Whether or not effective drugs come in time to turn around the world’s worst epidemic of the virus ravaging three West African countries, the world will want stockpiles to protect against inevitable future outbreaks, experts say.

Oct 23, 2014
Oct 23, 2014

Drugmakers may need indemnity for fast-tracked Ebola vaccines

LONDON/GENEVA (Reuters) – Drugmakers are looking for some kind of indemnity from governments or multilateral agencies for the widespread emergency use of new Ebola vaccines in Africa.

While the issue will not delay the industry’s ongoing work to accelerate production and clinical testing of three experimental vaccines, it is likely to be discussed at a high-level meeting in Geneva on Thursday.

Oct 22, 2014

Exclusive – EU earmarks $250 million to help develop Ebola vaccines: sources

LONDON (Reuters) – Europe is to plough 200 million euros (155.5 million pounds) into the development of Ebola vaccines, as well as drugs and diagnostic tests, according to two people with direct knowledge of the situation.

The funding is set to be announced this week under the Innovative Medicines Initiative (IMI), a public-private scheme jointly paid for by the pharmaceuticals industry and the European Commission.

Oct 22, 2014

EU earmarks $250 million to help develop Ebola vaccines: sources

LONDON (Reuters) – Europe is to plow 200 million euros ($250 million) into the development of Ebola vaccines, as well as drugs and diagnostic tests, according to two people with direct knowledge of the situation.

The funding is set to be announced this week under the Innovative Medicines Initiative (IMI), a public-private scheme jointly paid for by the pharmaceuticals industry and the European Commission.

Oct 22, 2014
    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben